CM313
Phase 1- Indications
- Immune thrombocytopenic purpura, Systemic lupus erythematosus, Multiple myeloma
Company intelligence / Profile preview
Timberlyne Therapeutics
San Diego, California, United Statesprnewswire.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Timberlyne Therapeutics launched in early 2025 with $180 million Series A financing to advance CM313, a potentially best-in-class anti-CD38 IgG1 monoclonal antibody. CM313 has demonstrated a high response rate—up to 95% in treatment-refractory ITP—in clinical studies and shows promise across multiple autoimmune diseases and cancers. The company holds exclusive rights outside greater China.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Keymed Biosciences – licensing partner for CM313 outside greater ChinaInvestors/Co-creators include Mountainfield Venture Partners, Abingworth, Bain Capital Life Sciences, Venrock Healthcare Capital Partners.
Beyond the preview
Go deeper on Timberlyne Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Timberlyne Therapeutics.